Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven

1. Cellular therapies like CAR T-cell and tumor-infiltrating lymphocyte therapies are showing remarkable responses in cancer treatment. 2. Equitable access to these therapies remains a significant challenge, influenced by logistical and financial burdens, institutional and regulatory protocols, disparities in referral and awareness, and racial and socioeconomic inequities. 3. Efforts at national and international levels are attempting to promote equity in access to cellular therapies.